Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Review

TRAIL and vitamins: opting for keys to castle of cancer proteome instead of open sesame

Authors: Ammad Ahmad Farooqi, Shahzad Bhatti, Muhammad Ismail

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

Cancer is a multifaceted molecular disorder that is modulated by a combination of genetic, metabolic and signal transduction aberrations, which severely impair the normal homeostasis of cell growth and death. Accumulating findings highlight the fact that different genetic alterations, such as mutations in tumor suppressor genes, might be related to distinct and differential sensitivity to targeted therapies. It is becoming increasingly apparent that a multipronged approach that addresses genetic milieu (alterations in upstream and/or parallel pathways) eventually determines the response of individual tumors to therapy. Cancerous cells often acquire the ability to evade death by attenuating cell death pathways that normally function to eliminate damaged and harmful cells. Therefore impaired cell death nanomachinery and withdrawal of death receptors from cell surface are some of major determinants for the development of chemotherapeutic resistance encountered during treatment. It is therefore essential to emphasize underlying factors which predispose cells to refractoriness against TRAIL mediated cell death pathway and the relevant regulatory components involved. We bring to limelight the strategies to re-sensitize TRAIL resistant cells via vitamins to induce apoptosis.
Appendix
Available only for authorised users
Literature
1.
Farooqi AA, Mukhtar S, Riaz AM, Waseem S, Minhaj S, Dilawar BA, Malik BA, Nawaz A, Bhatti S: Wnt and SHH in prostate cancer: trouble mongers occupy the TRAIL towards apoptosis. Cell Prolif. 2011, 44 (6): 508-515. 10.1111/j.1365-2184.2011.00784.x.CrossRefPubMed
2.
Farooqi AA, Rana A, Riaz AM, Khan A, Ali M, Javed S, Mukhtar S, Minhaj S, Rao JR, Rajpoot J, Amber R, Javed FA, Waqar-Un-Nisa , Khanum R, Bhatti S: NutriTRAILomics in prostate cancer: time to have two strings to one's bow. Mol Biol Rep. 2011, 39 (4): 4909-4914.CrossRefPubMed
3.
Farooqi AA, Waseem S, Ashraf MS, Iqbal MJ, Bhatti S: TRAIL and guardian angel of genome integrity: ATM boards TRAIL blazer. J Cancer Res Clin Oncol. 2011, 137 (9): 1283-1287. 10.1007/s00432-011-0996-y.CrossRefPubMed
4.
Sakoe Y, Sakoe K, Kirito K, Ozawa K, Komatsu N: FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia. Blood. 2010, 115 (18): 3787-3795. 10.1182/blood-2009-05-222976.CrossRefPubMed
5.
Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, Lynch PM, Moyer MP, Wen XF, Wu X: Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature. 2010, 464 (7291): 1058-1061. 10.1038/nature08871.PubMedCentralCrossRefPubMed
6.
Jiménez-Lara AM, Aranda A, Gronemeyer H: Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms. Mol Cancer. 2010, 9: 15-10.1186/1476-4598-9-15.PubMedCentralCrossRefPubMed
7.
Soucek K, Pacherník J, Kubala L, Vondrácek J, Hofmanová J, Kozubík A: Transforming growth factor-beta1 inhibits all-trans retinoic acid-induced apoptosis. Leuk Res. 2006, 30 (5): 607-623. 10.1016/j.leukres.2005.09.007.CrossRefPubMed
8.
Yin W, Rossin A, Clifford JL, Gronemeyer H: Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM. Oncogene. 2006, 25 (26): 3735-3744. 10.1038/sj.onc.1209410.CrossRefPubMed
9.
Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H: Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 2001, 7 (6): 680-686. 10.1038/89050.CrossRefPubMed
10.
Lim SC, Duong HQ, Choi JE, Lee TB, Kang JH, Oh SH, Han SI: Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis. 2011, 32 (5): 723-731. 10.1093/carcin/bgr038.CrossRefPubMed
11.
Fu L, Lin YD, Elrod HA, Yue P, Oh Y, Li B, Tao H, Chen GZ, Shin DM, Khuri FR, Sun SY: c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Mol Cancer. 2010, 9: 315-10.1186/1476-4598-9-315.PubMedCentralCrossRefPubMed
12.
Perez-Cruz I, Cárcamo JM, Golde DW: Caspase-8 dependent TRAIL-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis. 2007, 12 (1): 225-234. 10.1007/s10495-006-0475-0.CrossRefPubMed
13.
Yue P, Zhou Z, Khuri FR, Sun SY: Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biol Ther. 2006, 5 (5): 492-497. 10.4161/cbt.5.5.2565.CrossRefPubMed
14.
Zhang X, Li P, Bao J, Nicosia SV, Wang H, Enkemann SA, Bai W: Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J Biol Chem. 2005, 280 (42): 35458-35468. 10.1074/jbc.M506648200.PubMedCentralCrossRefPubMed
15.
Obradovic D, Zanca C, Vogl A, Trümbach D, Deussing J, Condorelli G, Rein T: Vitamin D3 signalling in the brain enhances the function of phosphoprotein enriched in astrocytes--15 kD (PEA-15). J Cell Mol Med. 2009, 13 (9B): 3315-3328. 10.1111/j.1582-4934.2009.00753.x.PubMedCentralCrossRefPubMed
16.
Kaler P, Galea V, Augenlicht L, Klampfer L: Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells. PLoS One. 2010, 5 (7): e11700-10.1371/journal.pone.0011700.PubMedCentralCrossRefPubMed
17.
Wang XF, Xie Y, Wang HG, Zhang Y, Duan XC, Lu ZJ: α-Tocopheryl succinate induces apoptosis in erbB2-expressing breast cancer cell via NF-κB pathway. Acta Pharmacol Sin. 2010, 31 (12): 1604-1610. 10.1038/aps.2010.171.PubMedCentralCrossRefPubMed
18.
Yu W, Park SK, Jia L, Tiwary R, Scott WW, Li J, Wang P, Simmons-Menchaca M, Sanders BG, Kline K: RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling. Cancer Lett. 2008, 259 (2): 165-176. 10.1016/j.canlet.2007.10.008.PubMedCentralCrossRefPubMed
19.
Yu W, Tiwary R, Li J, Park SK, Jia L, Xiong A, Simmons-Menchaca M, Sanders BG, Kline K: α-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway. Mol Carcinog. 2010, 49 (11): 964-973. 10.1002/mc.20681.CrossRefPubMed
20.
Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K: Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One. 2010, 5 (7): e11865-10.1371/journal.pone.0011865.PubMedCentralCrossRefPubMed
21.
Kannappan R, Ravindran J, Prasad S, Sung B, Yadav VR, Reuter S, Chaturvedi MM, Aggarwal BB: Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther. 2010, 9 (8): 2196-2207. 10.1158/1535-7163.MCT-10-0277.CrossRefPubMed
22.
Park SK, Sanders BG, Kline K: Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling. Breast Cancer Res Treat. 2010, 124 (2): 361-375. 10.1007/s10549-010-0786-2.CrossRefPubMed
23.
Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J, Procopio A: Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett. 2006, 580 (8): 1925-1931. 10.1016/j.febslet.2006.02.054.CrossRefPubMed
24.
Freeman RE, Neuzil J: Role of thioredoxin-1 in apoptosis induction by alpha-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells. FEBS Lett. 2006, 580 (11): 2671-2676. 10.1016/j.febslet.2006.04.019.CrossRefPubMed
25.
Tomasetti M, Rippo MR, Alleva R, Moretti S, Andera L, Neuzil J, Procopio A: Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. Br J Cancer. 2004, 90 (8): 1644-1653. 10.1038/sj.bjc.6601707.PubMedCentralCrossRefPubMed
26.
Weber T, Dalen H, Andera L, Nègre-Salvayre A, Augé N, Sticha M, Lloret A, Terman A, Witting PK, Higuchi M, Plasilova M, Zivny J, Gellert N, Weber C, Neuzil J: Mitochondria play a central role in apoptosis induced by alpha-tocopheryl succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. Biochemistry. 2003, 42 (14): 4277-4291. 10.1021/bi020527j.CrossRefPubMed
27.
Sylvester PW, Shah S: Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells. Asia Pac J Clin Nutr. 2005, 14 (4): 366-373.PubMed
28.
Dalen H, Neuzil J: Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. Br J Cancer. 2003, 88 (1): 153-158. 10.1038/sj.bjc.6600683.PubMedCentralCrossRefPubMed
29.
Weber T, Lu M, Andera L, Lahm H, Gellert N, Fariss MW, Korinek V, Sattler W, Ucker DS, Terman A, Schröder A, Erl W, Brunk UT, Coffey RJ, Weber C, Neuzil J: Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin Cancer Res. 2002, 8 (3): 863-869.PubMed
30.
Mazurek N, Byrd JC, Sun Y, Hafley M, Ramirez K, Burks J, Bresalier RS: Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. 2012, 19 (3): 523-533. 10.1038/cdd.2011.123.PubMedCentralCrossRefPubMed
31.
Símová S, Klíma M, Cermak L, Sourková V, Andera L: Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane. Apoptosis. 2008, 13 (3): 423-436. 10.1007/s10495-007-0171-8.CrossRefPubMed
32.
Akazawa Y, Mott JL, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME, Meng XW, Kohno S, Shah VH, Kaufmann SH, McNiven MA, Gores GJ: Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology. 2009, 136 (7): 2365-2376. 10.1053/j.gastro.2009.02.071. e1-7PubMedCentralCrossRefPubMed
33.
Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, Arai H, Tsuruo T, Fujita N: PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res. 2009, 7 (4): 557-569. 10.1158/1541-7786.MCR-08-0197.CrossRefPubMed
34.
Zhang Y, Yoshida T, Zhang B: TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells. Cancer Biol Ther. 2009, 8 (10): 917-922. 10.4161/cbt.8.10.8141.CrossRefPubMed
35.
Zhang Y, Zhang B: TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res. 2008, 6 (12): 1861-1871. 10.1158/1541-7786.MCR-08-0313.CrossRefPubMed
36.
Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Mazière AM, Klumperman J, Arnott D, Pham V, Scheller RH, Ashkenazi A: Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci USA. 2006, 103 (27): 10283-10288. 10.1073/pnas.0604044103.PubMedCentralCrossRefPubMed
37.
Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA: Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res. 2005, 65 (24): 11447-11458. 10.1158/0008-5472.CAN-05-1494.CrossRefPubMed
38.
Zhao X, Liu Y, Ma Q, Wang X, Jin H, Mehrpour M, Chen Q: Caveolin-1 negatively regulates TRAIL-induced apoptosis in human hepatocarcinoma cells. Biochem Biophys Res Commun. 2009, 378 (1): 21-26. 10.1016/j.bbrc.2008.10.123.CrossRefPubMed
39.
Rossin A, Derouet M, Abdel-Sater F, Hueber AO: Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J. 2009, 419 (1): 185-192. 10.1042/BJ20081212.CrossRefPubMed
40.
Xu L, Qu X, Luo Y, Zhang Y, Liu J, Qu J, Zhang L, Liu Y: Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts. Mol Med Report. 2011, 4 (3): 407-411. doi: 10.3892/mmr.2011.439
41.
Liu GC, Zhang J, Liu SG, Gao R, Long ZF, Tao K, Ma YF: Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis. World J Gastroenterol. 2009, 15 (7): 836-844. 10.3748/wjg.15.836.PubMedCentralCrossRefPubMed
42.
Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P: Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol. 2000, 164 (8): 3961-3970.CrossRefPubMed
43.
Oh Y, Jeon YJ, Hong GS, Kim I, Woo HN, Jung YK: Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells. Cell Death Differ. 2012, 13: 10.1038/cdd.2011.209.
44.
Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL: Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell. 2004, 15 (11): 5064-5074. 10.1091/mbc.E04-03-0184.PubMedCentralCrossRefPubMed
45.
Barrowman J, Bhandari D, Reinisch K, Ferro-Novick S: TRAPP complexes in membrane traffic: convergence through a common Rab. Nat Rev Mol Cell Biol. 2010, 11 (11): 759-763. 10.1038/nrm2999.CrossRefPubMed
46.
Zhao SL, Hong J, Xie ZQ, Tang JT, Su WY, Du W, Chen YX, Lu R, Sun DF, Fang JY: TRAPPC4-ERK2 interaction activates ERK1/2, modulates its nuclear localization and regulates proliferation and apoptosis of colorectal cancer cells. PLoS One. 2011, 6 (8): e23262-10.1371/journal.pone.0023262. Epub 2011 Aug 3PubMedCentralCrossRefPubMed
47.
Mir A, Kaufman L, Noor A, Motazacker MM, Jamil T, Azam M, Kahrizi K, Rafiq MA, Weksberg R, Nasr T, Naeem F, Tzschach A, Kuss AW, Ishak GE, Doherty D, Ropers HH, Barkovich AJ, Najmabadi H, Ayub M, Vincent JB: Identification of mutations in TRAPPC9, which encodes the NIK- and IKK-beta-binding protein, in nonsyndromic autosomal-recessive mental retardation. Am J Hum Genet. 2009, 85 (6): 909-915. 10.1016/j.ajhg.2009.11.009.PubMedCentralCrossRefPubMed
48.
Hu WH, Pendergast JS, Mo XM, Brambilla R, Bracchi-Ricard V, Li F, Walters WM, Blits B, He L, Schaal SM, Bethea JR: NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation. J Biol Chem. 2005, 280 (32): 29233-29241. 10.1074/jbc.M501670200.PubMedCentralCrossRefPubMed
49.
Kojima Y, Nakayama M, Nishina T, Nakano H, Koyanagi M, Takeda K, Okumura K, Yagita H: Importin β1 Protein-mediated Nuclear Localization of Death Receptor 5 (DR5) Limits DR5/Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Cell Death of Human Tumor Cells. J Biol Chem. 2011, 286 (50): 43383-43393. 10.1074/jbc.M111.309377.PubMedCentralCrossRefPubMed
50.
Tollefson AE, Toth K, Doronin K, Kuppuswamy M, Doronina OA, Lichtenstein DL, Hermiston TW, Smith CA, Wold WS: Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol. 2001, 75 (19): 8875-8887. 10.1128/JVI.75.19.8875-8887.2001.PubMedCentralCrossRefPubMed
51.
Xiao W, Ishdorj G, Sun J, Johnston JB, Gibson SB: Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses. Leuk Lymphoma. 2011, 52 (7): 1290-1301. 10.3109/10428194.2011.567317.CrossRefPubMed
52.
Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, Masci RK, Lee RM, Didonato JA, Lindner DJ: Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS One. 2007, 2 (12): e1313-10.1371/journal.pone.0001313.PubMedCentralCrossRefPubMed
53.
Chawla-Sarkar M, Bauer JA, Lupica JA, Morrison BH, Tang Z, Oates RK, Almasan A, DiDonato JA, Borden EC, Lindner DJ: Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem. 2003, 278 (41): 39461-39469. 10.1074/jbc.M306111200.PubMedCentralCrossRefPubMed
54.
Leon-Bollotte L, Subramaniam S, Cauvard O, Plenchette-Colas S, Paul C, Godard C, Martinez-Ruiz A, Legembre P, Jeannin JF, Bettaieb A: S-nitrosylation of the death receptor fas promotes fas ligand-mediated apoptosis in cancer cells. Gastroenterology. 2011, 140 (7): 2009-2018. 10.1053/j.gastro.2011.02.053. 2018CrossRefPubMed
55.
Tang Z, Bauer JA, Morrison B, Lindner DJ: Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4. Mol Cell Biol. 2006, 26 (15): 5588-5594. 10.1128/MCB.00199-06.PubMedCentralCrossRefPubMed
56.
Ishibashi M, Arai M, Tanaka S, Onda K, Hirano T: Antiproliferative and apoptosis-inducing effects of lipophilic vitamins on human melanoma A375 cells in vitro. Biol Pharm Bull. 2012, 35 (1): 10-17. 10.1248/bpb.35.10.CrossRefPubMed
57.
Ahmad J, Ahamed M, Akhtar MJ, Alrokayan SA, Siddiqui MA, Musarrat J, Al-Khedhairy AA: Apoptosis induction by silica nanoparticles mediated through reactive oxygen species in human liver cell line HepG2. Toxicol Appl Pharmacol. 2012, 259 (2): 160-168. 10.1016/j.taap.2011.12.020.CrossRefPubMed
Metadata
Title
TRAIL and vitamins: opting for keys to castle of cancer proteome instead of open sesame
Authors
Ammad Ahmad Farooqi
Shahzad Bhatti
Muhammad Ismail
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-22

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Primary research

Molecular network profiling of U373MG human glioblastoma cells following induction of apoptosis by novel marine-derived anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids

Primary research

Anticonvulsant and analgesic activities of crude extract and its fractions of the defensive secretion from the Mediterranean sponge, Spongia officinalis

Primary research

The differential expression pattern of the BMI-1, SALL4 and ABCA3 genes in myeloid leukemia

Primary research

ZIP8 expression in human proximal tubule cells, human urothelial cells transformed by Cd+2 and As+3 and in specimens of normal human urothelium and urothelial cancer

Primary research

The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase

Primary research

Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits